Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Reduction of inflammation and mitochondrial degeneration in mutant SOD1 mice through inhibition of voltage-gated potassium channel Kv1.3

Title: Reduction of inflammation and mitochondrial degeneration in mutant SOD1 mice through inhibition of voltage-gated potassium channel Kv1.3
Authors: Patrizia Ratano; Germana Cocozza; Cecilia Pinchera; Ludovica Maria Busdraghi; Iva Cantando; Katiuscia Martinello; Mariarosaria Scioli; Maria Rosito; Paola Bezzi; Sergio Fucile; Heike Wulff; Cristina Limatola; Giuseppina D'Alessandro
Contributors: Patrizia Ratano, Germana Cocozza , Cecilia Pinchera , Ludovica Maria Busdraghi , Iva Cantando , Katiuscia Martinello , Mariarosaria Scioli , Maria Rosito, Paola Bezzi , Sergio Fucile, Heike Wulff , Cristina Limatola, Giuseppina D'Alessandro; Ratano, Patrizia; Cocozza, Germana; Pinchera, Cecilia; Maria Busdraghi, Ludovica; Cantando, Iva; Martinello, Katiuscia; Scioli, Mariarosaria; Rosito, Maria; Bezzi, Paola; Fucile, Sergio; Wulff, Heike; Limatola, Cristina; D'Alessandro, Giuseppina
Publication Year: 2024
Collection: IRIS Unicas (Università degli Studi di Cassino e del Lazio Meridionale)
Description: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no effective therapy, causing progressive loss of motor neurons in the spinal cord, brainstem, and motor cortex. Regardless of its genetic or sporadic origin, there is currently no cure for ALS or therapy that can reverse or control its progression. In the present study, taking advantage of a human superoxide dismutase-1 mutant (hSOD1-G93A) mouse that recapitulates key pathological features of human ALS, we investigated the possible role of voltage-gated potassium channel Kv1.3 in disease progression. We found that chronic administration of the brain-penetrant Kv1.3 inhibitor, PAP-1 (40 mg/Kg), in early symptomatic mice (i) improves motor deficits and prolongs survival of diseased mice (ii) reduces astrocyte reactivity, microglial Kv1.3 expression, and serum pro-inflammatory soluble factors (iii) improves structural mitochondrial deficits in motor neuron mitochondria (iv) restores mitochondrial respiratory dysfunction. Taken together, these findings underscore the potential significance of Kv1.3 activity as a contributing factor to the metabolic disturbances observed in ALS. Consequently, targeting Kv1.3 presents a promising avenue for modulating disease progression, shedding new light on potential therapeutic strategies for ALS.
Document Type: article in journal/newspaper
File Description: ELETTRONICO
Language: English
Relation: volume:16; firstpage:1; lastpage:13; numberofpages:13; journal:FRONTIERS IN MOLECULAR NEUROSCIENCE; https://hdl.handle.net/11580/106585
DOI: 10.3389/fnmol.2023.1333745
Availability: https://hdl.handle.net/11580/106585; https://doi.org/10.3389/fnmol.2023.1333745; https://www.frontiersin.org/journals/molecular-neuroscience
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.FE2E9D48
Database: BASE